Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aptose Biosciences stock | 5.64

Own Aptose Biosciences stock in just a few minutes.


Fact checked

Aptose Biosciences Inc is a biotechnology business based in the US. Aptose Biosciences shares (APTO) are listed on the NASDAQ and all prices are listed in US Dollars. Aptose Biosciences employs 31 staff and has a market cap (total outstanding shares value) of USD$501.1 million.

How to buy shares in Aptose Biosciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Aptose Biosciences. Find the stock by name or ticker symbol: APTO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aptose Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$5.64, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Aptose Biosciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Aptose Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Aptose Biosciences's share price?

Since the stock market crash in March caused by coronavirus, Aptose Biosciences's share price has had significant negative movement.

Its last market close was USD$5.64, which is 34.80% down on its pre-crash value of USD$8.65 and 32.08% up on the lowest point reached during the March crash when the shares fell as low as USD$4.27.

If you had bought USD$1,000 worth of Aptose Biosciences shares at the start of February 2020, those shares would have been worth USD$742.28 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$794.39.

Aptose Biosciences share price

Use our graph to track the performance of APTO stocks over time.

Aptose Biosciences shares at a glance

Information last updated 2020-10-20.
Latest market close USD$5.64
52-week range USD$1.82 - USD$9.2525
50-day moving average USD$5.876
200-day moving average USD$6.3159
Wall St. target price USD$4.72
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.594

Buy Aptose Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aptose Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aptose Biosciences price performance over time

Historical closes compared with the close of $5.64 from 2020-11-16

1 week (2020-11-24) -9.32%
1 month (2020-10-30) 25.61%
3 months (2020-09-01) -8.29%
6 months (2020-06-01) -25.98%
1 year (2019-11-29) 108.12%
2 years (2018-11-30) 146.61%
3 years (2017-12-01) 180.60%
5 years (2015-12-01) 87.38%

Aptose Biosciences financials

Gross profit TTM USD$0
Return on assets TTM -43.14%
Return on equity TTM -74.05%
Profit margin 0%
Book value $1.038
Market capitalisation USD$501.1 million

TTM: trailing 12 months

Shorting Aptose Biosciences shares

There are currently 2.5 million Aptose Biosciences shares held short by investors – that's known as Aptose Biosciences's "short interest". This figure is 5.2% up from 2.4 million last month.

There are a few different ways that this level of interest in shorting Aptose Biosciences shares can be evaluated.

Aptose Biosciences's "short interest ratio" (SIR)

Aptose Biosciences's "short interest ratio" (SIR) is the quantity of Aptose Biosciences shares currently shorted divided by the average quantity of Aptose Biosciences shares traded daily (recently around 949141.19850187). Aptose Biosciences's SIR currently stands at 2.67. In other words for every 100,000 Aptose Biosciences shares traded daily on the market, roughly 2670 shares are currently held short.

However Aptose Biosciences's short interest can also be evaluated against the total number of Aptose Biosciences shares, or, against the total number of tradable Aptose Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aptose Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Aptose Biosciences shares in existence, roughly 30 shares are currently held short) or 0.0292% of the tradable shares (for every 100,000 tradable Aptose Biosciences shares, roughly 29 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aptose Biosciences.

Find out more about how you can short Aptose Biosciences stock.

Aptose Biosciences share dividends

We're not expecting Aptose Biosciences to pay a dividend over the next 12 months.

Have Aptose Biosciences's shares ever split?

Aptose Biosciences's shares were split on a 1:12 basis on 6 October 2014. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptose Biosciences shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Aptose Biosciences shares which in turn could have impacted Aptose Biosciences's share price.

Aptose Biosciences share price volatility

Over the last 12 months, Aptose Biosciences's shares have ranged in value from as little as $1.82 up to $9.2525. A popular way to gauge a stock's volatility is its "beta".

APTO.US volatility(beta: 0.83)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptose Biosciences's is 0.8283. This would suggest that Aptose Biosciences's shares are less volatile than average (for this exchange).

Aptose Biosciences overview

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1b clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase 1a/b clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site